Baseline best-corrected visual acuity (BCVA) did not impact meaningful visual and anatomic improvements in eyes with diabetic macular edema (DME) treated with aflibercept 8 mg, according to a posthoc analysis of the phase 2/3 PHOTON trial.
In an interview with HCPLive, Sean Adrean, MD, Retina Consultants of Orange County, indicated more patients treated with aflibercept 8 mg at baseline BCVA ≤20/40 also maintained their randomized dosing intervals versus those with baseline BCVA ≥20/50 through Week 48.
“When we look at 8 mg of aflibercept, we could be confident looking at the results of this trial that whether or not patients have 20/50 vision or worse or 20/40 or better vision, we can treat these patients with these extending dosing intervals,” Adrean told HCPLive. “We know that they’re going to maintain good vision and have an excellent response, even if they are out at 12 or 16 weeks compared with the 2 mg aflibercept at the 8-week dose.”
Highlights
0:08 Post-hoc analysis of PHOTON
1:00 Primary results in DME
3:11 Clinical profile of aflibercept 8 mg
3:52 Real-world application
4:35 Reducing treatment burden, extending intervals
5:39 Expectations for 2024
6:22 Concluding thoughts
Link to full article: www.hcplive.com/view/sean-adr...
More ARVO coverage: www.hcplive.com/conference/arvo
#retina #ophthalmology #conference